The Fed raised its benchmark interest rate to a range of 0.25% - 0.5%. After a continuous decline, most Chinese concept stocks have rebounded rapidly in the past two days, and some Chinese concept stocks have recovered their decline in the year.
fed announces interest rate hike
According to CCTV news, on March 16 local time, the Federal Reserve issued a policy statement announcing that it would raise the benchmark interest rate to the range of 0.25% - 0.5% Fed chairman Powell said at a news conference on the same day that the Fed would begin to reduce its holdings of nearly $9 trillion of assets on its balance sheet at the next policy meeting. This is the first time the Federal Reserve has raised interest rates since December 2018.
The Federal Reserve sent a signal on the same day that it is expected to raise interest rates six more times this year. The market generally believes that the benchmark interest rate is likely to reach 1.9% by the end of 2022. The Fed's policy-making committee hinted that it would raise interest rates three times in 2023 and raised inflation expectations for 2022, 2023 and 2024.
Yesterday, the three major U.S. stock indexes opened higher and walked higher. After the Federal Reserve announced the interest rate hike, there was a sharp intraday shock. The Dow and S & P 500 once turned green, then rebounded sharply and rose to the intraday high again. As of the close, the Dow rose 1.55%, the NASDAQ rose 3.77%, the largest increase in the year, and the S & P 500 rose 2.24%.
Previously, the market had certain expectations for the fed to raise interest rates. It was generally believed that the Fed would announce a 25 basis point interest rate increase. In 2022, the Fed would raise interest rates six to seven times. The result of this interest rate increase basically met the market expectations. After a short fluctuation, US stocks rose again rapidly, and finally rose slightly compared with the level before the interest rate increase.
zhonggai shares continue to perform the "great miracle day"
After a continuous decline, most Chinese stocks have rebounded rapidly in the past two days. Yesterday, Zhihu soared 79.17% and Jinshan cloud rose 72.27%. In the process of rebound in the past two days, Jinshan cloud's share price has doubled, with a cumulative increase of 116.02%. Ding Dong's vegetables, shells and Betta all rose by more than 60%, while jd.com, Baidu and Alibaba all rose by more than 30%.
Some Chinese concept stocks have recovered their decline in the year. Baidu's rise in the year has turned positive, with a cumulative increase of 1.4%. The decline of Ctrip, Netease and JD has narrowed, and the cumulative decline has been controlled within 10%.
Yesterday, the financial stability and Development Commission of the State Council held a special meeting. The meeting pointed out that the regulatory authorities of China and the United States have maintained good communication on China concept shares, made positive progress and are working to form a specific cooperation plan. The Chinese government continues to support all kinds of enterprises to list abroad. The special meeting effectively boosted market confidence, and many zhonggai stocks rose the highest since they went public.
domestic oral small molecule covid-19 drug
first release of phase I clinical data
Yesterday, Shanghai Junshi Biosciences Co.Ltd(688180) announced the results of three phase I clinical studies of oral nucleoside anti covid-19 drug vv116 tablets jointly developed by juntuo biology, a holding subsidiary, and Wangshan wangshui. The results showed that vv116 showed satisfactory safety and tolerance in healthy subjects, and repeated administration could maintain the effective antiviral concentration. This is the first phase I clinical data of domestic oral small molecule anti covid-19 drugs.
Previously, Pfizer covid-19 virus treatment drug paxlovid has been approved conditionally in China, and China Meheco Group Co.Ltd(600056) will be responsible for the agent operation of the product in 2022, with 8 trading boards in recent 11 days. Capital Securities believes that considering Pfizer's limited production capacity, high pricing, security and stability of the supply chain and other factors, domestic covid-19 oral medicine will still have a huge market. At present, several domestic covid-19 drug RdRp inhibitors have entered phase 3 clinical trials, including Shanghai Junshi Biosciences Co.Ltd(688180) , real organisms, etc. Domestic 3clpro inhibitors are still in the early stage of research and development. At present, Frontier Biotechnologies Inc(688221) (injection) has entered clinical phase 1.
According to the statistics of securities times · databao, A shares have 39 stocks in covid-19 therapeutic drugs and industrial chain. Yesterday, Wuhan Hiteck Biological Pharma Co.Ltd(300683) , China Meheco Group Co.Ltd(600056) rose by the limit, and others Ningbo Menovo Pharmaceutical Co.Ltd(603538) , Shanghai Kaibao Pharmaceutical Co.Ltd(300039) , Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) rose the most
Statistics show that 31 concept stocks have announced the performance forecast for 2021, of which 17 stocks are expected to increase . From the median value of the expected year-on-year increase of net profit, Tianjin Lisheng Pharmaceutical Co.Ltd(002393) , Nanjing Hicin Pharmaceutical Co.Ltd(300584) , Wuhan Hiteck Biological Pharma Co.Ltd(300683) are expected to increase by 1312.6%, 431.7% and 220.88% respectively.
from the perspective of capital flow, some concept stocks were favored by funds going north. In March, a total of 7 stocks were increased, and the shareholding of Tianjin Chase Sun Pharmaceutical Co.Ltd(300026) , Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) , Phichem Corporation(300398) and Phichem Corporation(300398) increased by more than 1 million shares HongRi pharmaceutical said that Xuebijing injection, the company's main product, has shown good efficacy and safety in the clinical practice of treating severe and dangerous cases of covid-19 pneumonia. It is recommended by the State Administration of traditional Chinese medicine to be included in the "three drugs and three parties" of anti epidemic traditional Chinese medicine.
